Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02311439
Other study ID # LAP001
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received December 4, 2014
Last updated December 5, 2014
Start date October 2014
Est. completion date April 2017

Study information

Verified date December 2014
Source Assiut University
Contact Ahmed Mohamed, MSc
Phone 00201221657931
Email a_allamnafady@yahoo.co.uk
Is FDA regulated No
Health authority Ethical Authority, Faculty of Medicine, Assiut University, Egypt ':'
Study type Interventional

Clinical Trial Summary

This prospective cohort, phase II, trial is studying induction chemotherapy combination, FOLFIRINOX regimen, consisted of oxaliplatin, irinotecan, leucovorin and fluorouracil (5-FU), for 4 cycles, followed by consolidation concurrent radiotherapy with capecitabine in non-progressed cases, in treating patients with locally advanced cancer pancreas.


Description:

Design & Methodology:

1. Nature of the study:

It is ( prospective cohort study).

2. Study subjects:

*Target Population: Patients, fulfilling the inclusion criteria for the research, will be selected from Assiut clinical oncology department in Assiut University Hospitals.

- Sample size:

20 patients.

- Characteristics of subjects:

- Inclusion criteria:

Disease characteristics:

- Histological and radiological confirmation of locally advanced cancer pancreas

- Inoperable disease

- Disease must be able to be encompassed within a radical radiotherapy treatment volume

- Not metastatic

Patient characteristics:

- ECOG performance status 0 or 1

- Life expectancy > 3 months.

- Glomerular filtration rate ≥ 60 mL/min.

- WBC > 3,000/mm³.

- Absolute neutrophil count > 1,500/mm³.

- Hemoglobin > 10.0 g/dL.

- Platelet count > 100,000/mm³.

- Alkaline phosphatase ≤ 1.5 times upper limit of normal (ULN)

- Gamma-glutamyl-transferase < 1.5 times ULN.

- Transaminases ≤ 1.5 times ULN.

- Bilirubin ≤ 1.5 times ULN.

- No medically unstable conditions (e.g., unstable diabetes, uncontrolled arterial hypertension, infection, hypercalcemia, or ischemic heart disease)

- Not pregnant or nursing.

- No other previous or current malignant disease likely to interfere with protocol treatment or comparisons

- No prior chemotherapy or radiotherapy.

3. Patients & Methods:

Patients are randomized to one treatment arm. Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 on day 1 only, administered as a 2-hour intravenous infusion, with the addition, after 30 minutes, of Irinotecan at a dose of 180 mg/m2 on day 1 only given as a 90-minute intravenous infusion. immediately will be followed by Leucovorin at a dose of 200 mg/m2, given as a 2- hour intravenous infusion, day 1 and day 2 This treatment will be followed by fluorouracil (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need.

In non-progressed cases, induction chemotherapy will be followed by consolidation radiotherapy concurrent with capecitabine 625 mg/m2 BID.

Radiotherapy :

A fractionated dose of 50.4Gy /28 fraction/15 MeV photon energy generated by Dual-energetic Linear Accelerator.

- Gross Target Volume (GTV): visible tumor and lymph nodes.

- Clinical Target Volume (CTV): [tumor/ affected lymph node + 1-2 cm] + regional lymphatics Lymphatics :corpus: upper and lower pancreaticoduodenal, superior and inferior pancreatic, celiac Head: corpus lymphatics + porta hepatis lymphatics Tail: corpus lymphatics (except pancreaticoduodenal LN) + splenic hilum LN

- PTV: CTV + 1-1.5 cm

- All patients will undergo a complete classical evaluation at the time of presentation which will be enrolled in a separate sheet for each patient. This will include a detailed history with estimation of the age of onset, the duration of the disease,.

- Detailed physical examination will be carried out Treatment evaluation . Laboratory examination include

- complete blood count (CBC),

- liver function test (LFT)

- Renal function test (RFT),

- Serum electrolytes at presentation and before each cycle of chemotherapy.

Radiographic examination include

- Abdominal Multi Detector Computed Tomography (MDCT Abdomen )

- Chest X-ray Before starting treatment, 2 weeks after ending phase 1 of treatment then 4 weeks after ending phase 2 of treatment then every 3 months for 18 months.

● Bone scan will be done in those complaining from bone pain; elevated serum alkaline phosphatase or transaminase level

- Quality of life is assessed at baseline, monthly for 6 months, and then at each follow-up visit.

After completion of study treatment, patients are followed periodically. Response Assessment : will be carried out, using (RECIST) Response Evaluation Criteria In Solid Tumors, Version 1.1 Chemotherapy Toxicity Assessment: will be carried out, using (CTCAE) Common Terminology Criteria for Adverse Events, Version 4.0

4. Data analysis:

Data will be analysed using the computer program, Statistical Package for the Social Science (SPSS V.16).

Expected outcomes:

The outcome of the study will be compared statistically with previous local and international trails.

Ethical considerations:

1. Risk-benefit assessment:

There is an acceptable risk may affect the patient in this research study as regard the acceptable side effects of Gemcitabine, Oxaliplatin and radiotherapy.

2. Confidentiality:

Any data taken from the patient either from history, the examination or the investigations will be very confidential.

3. Research statement:

All patients subjected to this study will be informed about the procedures of the research.

4. Informed consent:

The study procedures will be discussed to all patients and consent will be taken from them.

5. Other ethical concerns:

The research will be conducted only by scientifically qualified and trained personnel.


Recruitment information / eligibility

Status Recruiting
Enrollment 1
Est. completion date April 2017
Est. primary completion date November 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Disease characteristics:

- Histological and radiological confirmation of locally advanced cancer pancreas

- Inoperable disease

- Disease must be able to be encompassed within a radical radiotherapy treatment volume

- Not metastatic

Patient characteristics:

- ECOG performance status 0 or 1

- Life expectancy > 3 months.

- Glomerular filtration rate = 60 mL/min.

- WBC > 3,000/mm³.

- Absolute neutrophil count > 1,500/mm³.

- Hemoglobin > 10.0 g/dL.

- Platelet count > 100,000/mm³.

- Alkaline phosphatase = 1.5 times upper limit of normal (ULN)

- Gamma-glutamyl-transferase < 1.5 times ULN.

- Transaminases = 1.5 times ULN.

- Bilirubin = 1.5 times ULN.

- No medically unstable conditions (e.g., unstable diabetes, uncontrolled arterial hypertension, infection, hypercalcemia, or ischemic heart disease)

- Not pregnant or nursing.

- No other previous or current malignant disease likely to interfere with protocol treatment or comparisons

- No prior chemotherapy or radiotherapy.

Exclusion Criteria:

- ECOG performance status > 2

- Life expectancy < 3 months.

- Glomerular filtration rate < 30 mL/min.

- Absolute neutrophil count < 1,500/mm³.

- Alkaline phosphatase > 1.5 times upper limit of normal (ULN)

- Gamma-glutamyl-transferase > 1.5 times ULN.

- Transaminases>1.5 times ULN.

- Bilirubin >1.5 times ULN.

- medically unstable conditions (e.g., unstable diabetes, uncontrolled arterial hypertension, infection, hypercalcemia, or ischemic heart disease)

- pregnant or nursing.

- prior chemotherapy or radiotherapy.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
FOLFIRINOX + CRT
Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 D1, 2-hour I.V + Irinotecan 180 mg/m2 D1 90-minute I.V. + Leucovorin 200 mg/m2 2- hour I.V, D1,2 + (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need. In non-progressed cases, will be followed by consolidation concurrent radiotherapy with capecitabine 625 mg/m2 BID. Radiotherapy : A fractionated dose of 50.4Gy /28 fractions/15 MeV photon energy generated by Dual-energetic Linear Accelerator.

Locations

Country Name City State
Egypt Assiut University Hospitals Asyut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Other Progression Free Survival 6 months after finishing protocol Yes
Other Number of Cases will have radical surgery 6 months after enrolment Yes
Primary Number of Participants with Adverse Events as a Measure of Safety and Tolerability of FOLFIRINOX plus Concurrent Radiotherapy with Capecitabine will be carried out, using (CTCAE) Common Terminology Criteria for Adverse Events, Version 4.0 6 months after enrolment Yes
Secondary Tumor response will be carried out, using (RECIST) Response Evaluation Criteria In Solid Tumors, Version 1.1 6 months after enrolment Yes
See also
  Status Clinical Trial Phase
Terminated NCT02902484 - Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT04008537 - Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device N/A
Recruiting NCT04809935 - EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy Phase 4
Not yet recruiting NCT03659292 - Effects of Epidural Block on the Prognosis in Patients With Pancreatic Cancer Undergoing Distal Pancreatectomy N/A
Completed NCT03150615 - Enteral Nutrition After Pancreaticoduodenectomy N/A
Recruiting NCT02682394 - Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas N/A
Recruiting NCT05566743 - A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas Phase 2
Not yet recruiting NCT04049461 - Heterotopic Ossification in Abdominal Incision and Pancreatic Cancer
Recruiting NCT04164602 - The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
Active, not recruiting NCT04128332 - Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer N/A
Recruiting NCT03536793 - Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
Completed NCT02296736 - The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan
Withdrawn NCT04123574 - A Pilot Study of BXCL701 in Patients With Pancreatic Cancer Early Phase 1
Not yet recruiting NCT03278015 - Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT02905578 - A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) Phase 2
Completed NCT01446458 - Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer Phase 1
Recruiting NCT04677244 - Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT06148298 - Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer
Terminated NCT03451773 - M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas Phase 1/Phase 2